A Study of the Safety and Effectiveness of HBI-8000 with Nivolumab to Treat Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer


About this study

The purpose of this study is to evaluate the safety, tolerability and effectiveness of HBI-8000 when combined with a standard dose and regimen of nivolumab.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults at least 18 years of age.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
  • Subjects with histopathologically or cytologically confirmed diagnosis of non-uveal melanoma, RCC or NSCLC, for whom the use of nivolumab is indicated. NSCLC subjects with EGFR or ALK genomic aberrations in tumor should have disease progression on FDA-approved therapy for these aberrations prior to receiving nivolumab. (Phase 1b).
  • Subjects with histopathologically or cytologically confirmed diagnosis of non-uveal melanoma, or NSCLC, for whom the use of nivolumab is indicated (Phase 2 expansion). With Protocol Amendment 5, subjects with NSCLC are not eligible for enrollment.
  • Non-uveal melanoma and NSCLC patients whose disease has progressed after achieving stable disease (SD) for at least 3 months, with partial response (PR) or complete response) CR as the best response that has been documented by imaging studies on previous treatment with a PD-L1 inhibitor with proven efficacy (Phase 2 expansion). With Protocol Amendment 5, subjects with NSCLC are not eligible for enrollment.
  • Subject must have at least one measurable target lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.  Melanoma subjects participating in the optional serial tumor biopsy sub-study must have tumor tissue available from a metastatic or unresectable site for PD-L1 and correlative biomarker analysis.
  • All prior systemic therapy (chemotherapy, mutation targeting therapy, immune checkpoint therapy), surgical or radiation treatment must have been completed at least 4 weeks before study drug administration (2 weeks for palliative radiotherapy, 1 week for minor surgery) pending full recovery from therapy.
  • The following laboratory results within 7 days prior to study drug administration: Adequate hematopoietic, electrolyte, hepatic, and renal laboratory findings as defined below: white blood cells (WBC) ≥ 3000/μL, neutrophils ≥ 1500/μL, platelets ≥ 100x103/μL, hemoglobin ≥ 9.0 g/dL independent of transfusion, creatinine ≤ 1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN), alkaline phosphatase ≤ 2.5 x ULN unless bone metastases present, bilirubin ≤ 1.5 x ULN (unless known Gilbert’s disease where it must be ≤ 3 x ULN) and serum albumin ≥ 3.0 g/dL.
  • Life expectancy ≥ 12 weeks.
  • A negative serum pregnancy test at baseline for women of childbearing potential.
  • Are willing to abstain from heterosexual activity or practice physical barrier contraception prior to time of study entry to at least 5 months after the last day of treatment.
  • Have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • History of Grade 3 or above hypersensitivity reactions to other monoclonal antibodies.
  • Subjects with a history of a cardiovascular illness including:
    • Congestive heart failure (New York Heart Association Grade III or IV);
    • Unstable angina or myocardial infarction within the previous 6 months; or
    • Symptomatic cardiac arrhythmia despite medical management. In addition, for Phase 1b only: QTc (Fridericia’s correction) (QTcF) > 450 ms in male, and > 470 ms in female, congenital long QT syndrome.
  • Uncontrolled hypertension, systolic blood pressure (SBP) > 160 mmHg or diastolic blood pressure (DBP) >100 mmHg.
  • Subjects with active brain metastasis; previously treated brain metastasis is allowed if it has been stable for 4 weeks or more and not requiring steroids.
  • Presence of leptomeningeal disease.  History of hemorrhagic diarrhea, inflammatory bowel disease, active uncontrolled peptic ulcer disease or recurrent pleural effusion requiring repetitive palliative thoracentesis within 3 months prior to study entry, except for subjects with a pleurex port; and immune-mediated toxicity leading to treatment discontinuation.
  • Active, known, or suspected serious autoimmune disease, except for type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia).
  • Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
  • Known history of testing positive for human immunodeficiency virus (HIV), known acquired immunodeficiency syndrome (AIDS).
  • Active hepatitis B (serum hepatitis B surface antigen [HBV sAg] positive), or hepatitis C (hepatitis C virus [HCV] antibody test or serum hepatitis C ribonucleic acid [RNA] positive) indicating acute or chronic infection.
  • Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids are permitted.
  • Use of other investigational agent (drug not marketed for any indication) within 28 days or at least 5 half-lives (whichever is shorter) before study drug administration.
  • Pregnant or breast-feeding women.
  • Second malignancy unless in remission for 2 years, except for non-melanomatous skin cancer, carcinoma in situ of the cervix treated with curative intent, curatively treated prostate cancer with prostate-specific antigen (PSA) < 0.1 ng/mL.
  • Underlying medical conditions that, in the Investigator’s opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events.
  • Unwilling or unable to comply with procedures required in this protocol.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Thai Ho, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer